Abrégé

Provided in the present invention are a 2-aminothiazole compound derivative and the use thereof. The compound has a chemical structure of general formula (I) as shown in the following formula. The compound derivative provided in the present invention has an inhibitory activity against dihydroorotate dehydrogenase (DHODH), and is expected to be used in the preparation of a drug for preventing and/or treating diseases related to DHODH.

Classes IPC  ?

• C07D 277/60 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés condensés avec des carbocycles ou avec des systèmes carbocycliques
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• A61K 31/428 - Thiazoles condensés avec des carbocycles
• A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
• A61P 37/02 - Immunomodulateurs
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 31/12 - Antiviraux

Abrégé

A method for preparing chondroitin with a controllable molecular weight. The chondroitin is obtained by taking an initiator as an initial polymerization substrate; sequentially bonding n comonomers at a non-reducing end of the initiator, wherein the comonomers are formed from acetylated hexosamine and uronic acid by means of a glycosidic bond; and the comonomers and the initiator being polymerized under the action of catalysis of a polymerase to form a polysaccharide with a certain molecular weight, namely the chondroitin. The chondroitin preparation technology can prepare chondroitin for which the molecular weight varies in a linear manner, the controllable molecular weight range is wide, and the molecular weight distribution is narrow. The molecular weight range can include 10,000-5,000,000; 100,000-4,000,000; 250,000-3,000,000; 350,000-2,000,000; 500,000-1,000,000; 20,000-300,000; 1,000-70,000; 70,000-300,000; 350,000-660,000; 380,000-900,000.

Classes IPC  ?

• C12P 19/28 - N-glucosides
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)

Abrégé

A cationic lipid compound, a composition comprising the cationic lipid compound, and a use. A compound is as represented by general formula (I). Also provided are a cationic lipid compound comprising the compound, or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof. The present application also relates to an immune cell-targeted lipid nanoparticle, and a screening method therefor and a use thereof. Specifically disclosed is a use of the compound of formula (I), or the pharmaceutically acceptable salt, prodrug, or stereoisomer thereof in targeting immune cells, and also disclosed are a method for in vitro screening of lipid nanoparticles and a method for screening lipid nanoparticles suitable for delivering mRNA to various immune cells in vivo.

Classes IPC  ?

• C07C 229/16 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons à des atomes de carbone de radicaux hydrocarbonés substitués par des groupes amino ou carboxyle, p. ex. acide éthylènediaminetétra-acétique, acides iminodiacétiques
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• C07C 237/10 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone acyclique d'un radical hydrocarboné substitué par des atomes d'azote ne faisant pas partie de groupes nitro ou nitroso
• C07D 295/13 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants liés à la même chaîne carbonée, qui n'est pas interrompue par des cycles carbocycliques à une chaîne acyclique saturée
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique

Abrégé

Provided are a pharmaceutical composition for preventing and/or treating neurodegenerative diseases and use thereof. The pharmaceutical composition comprises rivastigmine, liraglutide, and derivatives thereof; the pharmaceutical composition further comprises a sustained-release system, the sustained-release system can interact with the rivastigmine, the liraglutide, and the derivatives thereof to form a copolymer that enables sustained drug release, and the sustained-release system is a triblock hydrogel sustained-release system. The combination of the liraglutide and the rivastigmine can ameliorate the learning and memory impairments associated with Alzheimer's disease, with the effect superior to monotherapy and exhibiting a synergistic effect.

Classes IPC  ?

• A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
• A61K 38/26 - Glucagons
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

An ammonia-driven hydrogel dehydration-desalination method is provided. The method includes the following steps: a hydrogel soaking step: soaking a hydrogel in salt water; and an ammonia dehydration step: placing the hydrogel after water absorption in a closed container, and introducing ammonia for making the ammonia dissolved on a surface of the hydrogel to produce a high osmotic pressure, so as to promote the permeation of water molecules out of the hydrogel and to obtain produced water

Classes IPC  ?

• C02F 1/26 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par extraction
• C02F 1/44 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dialyse, osmose ou osmose inverse
• C02F 101/12 - Halogènes ou composés halogénés
• C02F 103/08 - Eau de mer, p. ex. pour le dessalement

Abrégé

Use of 6-phosphogluconic acid and a derivative thereof in preparing a medicament for preventing or treating glycometabolism disorder diseases. The 6-phosphogluconic acid and the derivative thereof are a type of cell glycometabolism regulators and diabetes treatment agents, have a remarkable regulation effect on islet alpha cells, and can be further prepared into a medicament for preventing or treating diabetes and other glycometabolism disorder diseases.

Classes IPC  ?

• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

Provided is a method for biosynthesis of a human structural material type XVII collagen. The collagen comprises the amino acid sequence shown in SEQ ID NO: 2 or a variant amino acid sequence after mutation of the amino acid sequence. The variant amino acid sequence retains the function of the amino acid sequence as shown in SEQ ID NO: 2. The collagen can promote cell adhesion and has a triple helix structure.

Classes IPC  ?

• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C07K 1/18 - Chromatographie d'échange d'ions
• A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
• A61K 8/65 - CollagèneGélatineKératineLeurs dérivés ou produits de dégradation
• A61Q 19/00 - Préparations pour les soins de la peau
• A61L 15/32 - Protéines, polypeptidesLeurs produits de dégradation ou leurs dérivés, p. ex. albumine, collagène, fibrine, gélatine
• A61L 27/24 - Collagène
• A61L 31/04 - Matériaux macromoléculaires
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 5/07 - Cellules animales ou tissus animaux
• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats

Abrégé

A continuous-flow preparation method for an amino alcohol compound using a micro-reaction system. The micro-reaction system includes a feed pump, a micromixer, a microchannel reactor, and a back pressure valve. An aldehyde compound and an amine compound are simultaneously fed to the micro-mixer for mixing to obtain a mixed solution. The mixed solution is directly fed to the micro-channel reactor and undergoes an addition reaction. The reaction mixture is collected, and subjected to concentration, separation and purification to obtain the desired amino alcohol compound.

Classes IPC  ?

• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
• C07C 213/08 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions n'impliquant pas la formation de groupes amino, de groupes hydroxy ou de groupes hydroxy éthérifiés ou estérifiés

Abrégé

An embodiment of the present disclosure provides a leveling agent, which is specifically a polypyridine compound, where the polypyridine compound includes a structural unit shown in Formula (I) or a protonated product of the structural unit shown in Formula (I): An embodiment of the present disclosure provides a leveling agent, which is specifically a polypyridine compound, where the polypyridine compound includes a structural unit shown in Formula (I) or a protonated product of the structural unit shown in Formula (I): An embodiment of the present disclosure provides a leveling agent, which is specifically a polypyridine compound, where the polypyridine compound includes a structural unit shown in Formula (I) or a protonated product of the structural unit shown in Formula (I): In Formula (I), R1 and R2 are independently any one of the following: substituted or unsubstituted alkylene, substituted or unsubstituted arylene, substituted or unsubstituted arylene alkyl, substituted or unsubstituted alkylene aryl, alkylene containing an ether oxygen atom, ester, and/or imide, arylene containing an ether oxygen atom, ester, and/or imide, arylene alkyl containing an ether oxygen atom, ester, and/or imide, and alkylene aryl containing an ether oxygen atom, ester, and/or imide; and R3 is any one of groups such as a single bond, substituted or unsubstituted alkylene, substituted or unsubstituted arylene, substituted or unsubstituted arylene alkyl, and substituted or unsubstituted alkylene aryl.

Classes IPC  ?

• C25D 3/38 - Dépôt électrochimiqueBains utilisés à partir de solutions de cuivre

Abrégé

Provided is an in-vivo in-situ CAR immunotherapy and cancer vaccine combined therapy strategy based on circular RNA, which is a novel tumor immunotherapy that combines the cyclic RNA-based in-vivo in-situ CAR-T/M technology and the circular RNA cancer vaccine technology. This novel tumor immunotherapy enables rapid and efficient generation of CAR-T/M cells in vivo and further produces an enhanced collaborative anti-tumor immunotherapy effect with the synergistic action of the corresponding circular RNA cancer vaccine. In addition, a specific non-complementary region of an I-type intron from tetrahymena is split, and thus in-vitro efficient RNA cyclization can be achieved by means of self-splicing of the I-type intron without requiring homologous arms or additional GTP catalysis.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique

Abrégé

Disclosed in the present application are compounds having the activity of degrading GSPT1 and an application thereof. The compounds disclosed in the present application have the activity of degrading GSPT1, and can be used for preparing drugs for treating GSPT1 activity-related diseases.

Classes IPC  ?

• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61P 35/00 - Agents anticancéreux
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles

Abrégé

A hydrazone compound, a pharmaceutical composition thereof, and an application thereof. Specifically, provided is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof. The compound has one or more of the advantages below: good water solubility; relatively low cytotoxicity; good inhibitory activity on Arf1 activation; and possessing and inducing relatively strong anti-tumor immunity.

Classes IPC  ?

• C07D 495/04 - Systèmes condensés en ortho
• C07D 209/02 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/15 - Oximes (C=N-O-)Hydrazines ( N-N)Hydrazones (N-N=)
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present disclosure relates to the field of biomedicine, in particular, to a CD300LD inhibitor and use thereof in the preparation of tumor immunotherapy products. In the present disclosure, the CD300LD inhibitor regulates the migration and function of PMN-MDSC cells by modulating S100A8/A9 in its downstream signaling pathway, and plays an important role in the establishment of the tumor microenvironment. The polypeptide isolated by the present disclosure is used as a CD300LD inhibitor, and CD300LD-ECD protein can inhibit CD300LD by competitive binding, thus inhibiting tumor development. When tumor-bearing mice are treated with this peptide, the development of tumors can be significantly inhibited. In addition, CD300LD-ECD has a significant anti-tumor synergistic effect with PD1 antibody.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

A heterojunction sensing-storage-computing device and a manufacturing method therefor. The heterojunction sensing-storage-computing device comprises: a substrate; a back gate electrode, formed on the substrate; a first gate dielectric layer/second gate dielectric layer/third gate dielectric layer stack, formed on the back gate electrode; one-dimensional nanowires, which are semiconductor materials having a response in a near-infrared band and are formed on the third gate dielectric layer; two-dimensional layered semiconductor materials, which are semiconductor materials having a response in a visible light band, are formed on the third gate dielectric layer, and overlap with the one-dimensional nanowires to form one-dimensional and two-dimensional heterojunctions as channel layers; and source electrodes and drain electrodes, formed on two sides of the corresponding channel layers. Information sensing, storage and computing functions are integrated in a same device unit, thereby improving a photoelectric sensing range and sensitivity of the device, and realizing the storage-computing integrated application with the information sensing capability in the visible-near-infrared band.

Classes IPC  ?

• H01L 29/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails des corps semi-conducteurs ou de leurs électrodes
• H01L 31/113 - Dispositifs sensibles au rayonnement infrarouge, visible ou ultraviolet caractérisés par un fonctionnement par effet de champ, p.ex. phototransistor à effet de champ à jonction du type conducteur-isolant-semi-conducteur, p.ex. transistor à effet de champ métal-isolant-semi-conducteur
• H01L 31/0248 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails caractérisés par leurs corps semi-conducteurs
• H01L 31/18 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives

Abrégé

By combining a federated learning model and a low earth orbit (LEO) satellite network, the present invention provides a general federated learning framework over an LEO satellite network (FedSN) for achieving federated learning. The FedSN is composed of two main components: a sub-structure scheme and pseudo-synchronous model aggregation. The sub-structure scheme comprises sub-structure customization, distribution and aggregation methods, and respectively solves problems such as resource limitations, training imbalance, staleness of intra-group models. According to a pseudo-synchronous model aggregation strategy, the difference between weights of models is brought into a weight function, and a buffer-based aggregation method is developed, so that the staleness of inter-group models is reduced. Extensive experimental results show that a FedSN framework is superior to a state-of-the-art baseline. The present invention shows and improves the potential of deploying a FedSN on an LEO satellite network.

Classes IPC  ?

• H04B 7/185 - Stations spatiales ou aériennes
• G06N 3/098 - Apprentissage distribué, p. ex. apprentissage fédéré

Abrégé

A blowtorch (100) and a plasma deposition apparatus (200). The blowtorch (100) comprises a first pipe fitting (10), a second pipe fitting (20), a third pipe fitting (30), and an auxiliary air inlet pipe (40). The first pipe fitting (10) defines a feeding channel (11), and the first pipe fitting (10) has a feeding end (12) and a discharging end (13) which are oppositely arranged in the length direction of the first pipe fitting. The second pipe fitting (20) is sleeved on the outer side of the first pipe fitting (10), and the second pipe fitting (20) and the first pipe fitting (10) define an auxiliary channel (Q1). The third pipe fitting (30) is sleeved on the outer side of the second pipe fitting (20), and the third pipe fitting (30) and the second pipe fitting (20) define a first cooling channel (Q2). The auxiliary air inlet pipe (40) is connected to the second pipe fitting (20), and the radial distance between the auxiliary air inlet pipe (40) and the second pipe fitting (20) gradually decreases in a direction moving close to the discharging end. The blowtorch structure can improve the deposition efficiency of the blowtorch.

Classes IPC  ?

• C23C 16/453 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement en faisant passer les gaz de réaction à travers des brûleurs ou des torches, p. ex. CVD sous pression atmosphérique

Abrégé

Embodiments of the disclosure relate to a method, an apparatus, a device, and a storage medium for information processing. The method proposed herein includes: obtaining a sample question and policy information for solving the sample question; determining, by splitting the policy information, an inference process corresponding to at least one intermediate solution state of the sample question; generating at least one input sample by combining the sample question and the inference process; and adjusting a target model based on the at least one input sample and answer information of at least one sample question.

Classes IPC  ?

• G06N 5/04 - Modèles d’inférence ou de raisonnement

Abrégé

Provided is a tumor tissue resection-guiding device, comprising a sampling assembly (100) configured for collecting a sample from a tissue surface, a detecting assembly (200) configured for detecting a biomarker in the sample, and a mapping assembly (300) configured for integrating a detection result of the biomarker to an image of the tissue surface.

Classes IPC  ?

• A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie
• G01N 21/65 - Diffusion de Raman

Abrégé

Provided are an isoquinolinone compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a prodrug molecule, and a mixture thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as an FABP4/FABP5 dual-targeting inhibitor. Related aryl carboxylic acid compounds can be used for preparing drugs for treating metabolic diseases (such as diabetes, insulin resistance, hyperlipidemia, and atherosclerosis), autoimmune diseases and cancers. Provided are an isoquinolinone compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a prodrug molecule, and a mixture thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as an FABP4/FABP5 dual-targeting inhibitor. Related aryl carboxylic acid compounds can be used for preparing drugs for treating metabolic diseases (such as diabetes, insulin resistance, hyperlipidemia, and atherosclerosis), autoimmune diseases and cancers.

Classes IPC  ?

• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• C07D 217/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/10 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques

Abrégé

A method for continuous-flow amination for an alkyl carboxylic acid compound is provided, in which an amination reagent and a catalyst are mixed in a first micro-mixer and then preheated in a preheater. The mixture is mixed with a substituted alkyl carboxylic acid solution in a second micro-mixer and reacted in a dynamic flow reactor to produce a mixture including a carboxyl-containing organic amine product. Then, the mixture is subjected to gas-liquid separation, and the liquid phase is collected and filtered to obtain a first filtrate and a first filter residue. The first filter residue is mixed with a base solution under stirring and filtered to obtain a second filtrate and a second filter residue. The second filter residue was dried to yield a high-purity carboxyl-containing organic amine product.

Classes IPC  ?

• C07C 227/10 - Formation de groupes amino dans des composés contenant des groupes carboxyle avec augmentation simultanée du nombre d'atomes de carbone dans le squelette carboné
• B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
• C07C 227/40 - SéparationPurification

Abrégé

A combination of SNP loci for paternity testing, a detection primer pair and an application thereof are provided, belonging to the application research of forensic molecular genetics. The combination of SNP loci includes 520 SNP loci. Based on the combination of SNP loci, all the selected loci in the population conform to Hardy-Weinberg equilibrium (corrected by Bonferroni), and each locus is not linked and is in linkage equilibrium. When selecting loci, references are made to various databases, relevant literature, and genetic markers widely used in forensic science, which allows for obtaining more genetic information and higher forensic efficacy. It is conducive to forensic applications such as individual identification of difficult biological samples and prenatal paternity test of maternal peripheral blood.

Classes IPC  ?

• G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6869 - Méthodes de séquençage

Abrégé

Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

Provided is a preparation method for a group I intron-based circular RNA, relating to the technical field of circular RNAs. A specific non-complementary region of a group I intron is split, the method can be generalized to other group I introns, and by means of the principle of ribozyme self-splicing, preparation of a circular RNA is achieved. By optimizing a sequence, when there is no homology arm, efficient cyclization can be achieved without adding GTP for catalysis. In terms of vaccines, a new method for preparing an anti-infectious disease and anti-tumor circular RNA vaccine that produces a high neutralizing antibody and a T cell immune response is provided. In terms of chimeric antigen receptor (CAR) therapy, a method for in vivo engineering of immune cells (including T cells, macrophages, etc.) using a circular RNA-based "off-the-shelf" in vivo CAR is provided, and an anti-tumor immunotherapy drug can be developed and prepared.

Classes IPC  ?

• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

A method of preparing an alkyl phosphate compound based on a micro-reaction system. The micro-reaction system includes a feed pump, a first micro-mixer, a second micro-mixer, a first micro-channel reactor, a second micro-channel reactor and a back-pressure device, where the first micro-mixer, the second micro-mixer, the first micro-channel reactor, the second micro-channel reactor and the back-pressure device are sequentially connected. The method includes the following steps. An alkylamine compound and an acid-binding agent are simultaneously fed to a first micro-mixer for mixing and then to the first micro-channel reactor for pre-reaction to obtain a pre-reaction solution. The pre-reaction solution and a phosphate or phosphite are simultaneously fed to the second micro-mixer for mixing to obtain a first reaction mixture. The first reaction mixture is fed to the second micro-channel reactor to carry out a condensation reaction under a back pressure condition and is concentrated to obtain the final product.

Classes IPC  ?

• C07F 9/50 - Organo-phospines
• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
• C07F 9/46 - Acides phosphineux [R2=P—OH]Acides thiophosphineux

Abrégé

A ribonucleic acid (RNA) in-vitro cyclization and rolling circle translation (RCT) method based on a group I intron, and a use. A specific non-complementary region of the group I intron is split to obtain an RNA construct, the preparation of a "scarless" circular RNA is implemented by means of the principle of ribozyme self-splicing, and the method is generalized to other group I introns. By optimizing a split structure, in the absence of homology arms, efficient cyclization can be achieved without the need for additional GTP catalysis. Additionally, the components of the RNA construct are optimized, thereby further improving the cyclization efficiency. An RCT technology platform based on a CITE sequence is established, thereby greatly improving the expression level of a protein or polypeptide. It has been verified that the cyclization and RCT method shows potential in vaccine and CAR treatment, and is expected to be used in the clinical treatment of various diseases.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/65 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression utilisant des marqueurs
• C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present disclosure provides protein degraders developed based on BCL-2 family protein lig and compounds, including compounds of Formula (I) or their salts, enantiomers, stereoisomers, solvates, prodrugs, or polymorphs, and their applications for treating diseases. The present disclosure provides protein degraders developed based on BCL-2 family protein lig and compounds, including compounds of Formula (I) or their salts, enantiomers, stereoisomers, solvates, prodrugs, or polymorphs, and their applications for treating diseases.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique

Abrégé

Provided are a whole-process targeting polypeptide, a pharmaceutical complex thereof, a drug delivery system and the use thereof. The whole-process targeting polypeptide comprises pHA and a VAP which are covalently linked by means of a bridging structure; and the VAP is LVAP, a retro polypeptide of LVAP, DVAP or SVAP, the amino acid sequence of LVAP being as shown as SEQ ID NO: 1, SVAP being a D-configuration polypeptide of LVAP, DVAP being a D-configuration polypeptide of a retro polypeptide of LVAP, and the bridging structure being amino-monoethylene glycol-carboxylic acid, or a derivative thereof. The whole-process targeting polypeptide can cross the blood-brain barrier and target new blood vessels of tumors, can cross the blood-tumor barrier and target tumor vasculogenic mimicry-derived channels, tumor cells and stem cells thereof, and has better tumor cell affinity, anti-tumor treatment effect and in-vivo safety effect. In addition, when being combined with chemotherapeutic drugs, the pharmaceutical complex or the drug delivery system has a synergistic effect, thereby remarkably improving the anti-tumor pharmaceutical effect.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 51/08 - Peptides, p. ex. protéines
• A61K 49/00 - Préparations pour examen in vivo
• A61K 49/14 - Peptides, p. ex. protéines
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention provides a compound represented by general formula (I) or a pharmaceutically acceptable salt, precursor, or solvate thereof, and a use thereof in the preparation of a drug for diagnosing diabetic nephropathy. General formula (I), wherein X is selected from carbon or nitrogen; R1is selected from hydrogen or alkyl; R2is one or more substituents on the benzene ring or the pyridine ring, and R2is independently selected from one or more of hydrogen, halogen, hydroxyl, cyano, nitro, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkoxy, C1-C6 alkylamino, C3-C6 cycloalkylamino, halo C1-C6 alkyl, halo C3-C6 cycloalkyl, halo C1-C6 alkoxy, halo C3-C6 cycloalkoxy, halo C1-C6 alkylamino, halo C3-C6 cycloalkylamino, C6-C8 aryl, or C5-C8 heteroaryl, and in these substituents represented by R2, at least one atom or the entire substituent is replaced by a radionuclide. The drug and method for diagnosing diabetic nephropathy according to the present invention relate to non-invasive diagnosis technology and have the advantages of causing less pain to a subject and having less contraindications.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 51/04 - Composés organiques
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins

Abrégé

Provided in the present invention are a fusion protein for inactivating a coronavirus and the use thereof in the treatment of a coronavirus infection. The fusion protein comprises an ACE2 peptidase domain and a coronavirus polypeptide therapeutic agent targeting an HR1 domain, which are directly linked or are linked via a linker. The ACE2 peptidase domain comprises an amino acid sequence as shown in SEQ ID NO: 1.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)

Abrégé

Polyphenol compounds, a preparation method therefor and the use thereof. Specifically provided are polyphenol compounds shown as formula X, stereoisomers thereof, or pharmaceutically acceptable salts thereof. The compounds have a remarkable protection effect on an OGD/R-induced in-vitro cerebral ischemia model, can significantly inhibit the inflammation and apoptosis reaction of neurons, and can reduce the volume of cerebral infarction in mice suffering from cerebral ischemia. Additionally, the compounds have reduced polarity, thus improving the oral bioavailability and the proportion of passing through the blood-brain barrier.

Classes IPC  ?

• C07D 311/62 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des substituants autres que des atomes d'oxygène ou de soufre en position 2 ou 4 avec des radicaux aryle liés en position 2 avec des atomes d'oxygène liés directement en position 3, p. ex. anthocyanidines
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present invention relates to the technical field of lithium-ion battery materials, and particularly relates to a solvent-free synthesis method for an ordered mesoporous carbon material, a silicon-carbon negative electrode material derived therefrom and the use thereof. In the present invention, a surfactant, a carbon precursor and a catalyst are ground and uniformly mixed to perform a reaction, and are then carbonized under atmosphere protection to obtain an ordered mesoporous carbon material; and furthermore, a silane is introduced into a container, in which the ordered mesoporous carbon material is placed, for reaction, so as to obtain a silicon-carbon negative electrode material. The ordered mesoporous carbon material in the present invention has a uniform pore diameter and good pore connectivity, can ensure uniform deposition of monatomic silicon, and effectively improves the stability and consistency of the finally obtained silicon-carbon material.

Classes IPC  ?

• C01B 32/05 - Préparation ou purification du carbone non couvertes par les groupes , , ,

Abrégé

An exposure device for exposing microorganisms to gaseous pollutants and a corresponding in-situ multi-toxicity endpoint detection system are provided. The detection system based on the exposure device disclosed in the present application may perform controlled accumulation of pollutants in air, and implements in-situ, comprehensive, quick, and low-cost assessment of toxicity effects of pollutants in air of a target site. The exposure device and the detection system disclosed in the present application can effectively avoid toxicity distortion caused by complex collection and transfer process, complex chemical reactions in a liquid elution process in conventional toxicity detection methods for gaseous pollutants.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse

Abrégé

A rapidly constructed three-dimensional model of a microbial film exposed at an air-liquid interface and a preparation method thereof, as well as a hydrogel bead containing microorganisms immobilized at an air-liquid interface in an exposed state and a preparation method thereof. The model includes a hydrogel material containing gradually releasable nutrients, as a core scaffold; a hydrogel film attached to a surface of core and wrapping microorganisms, as a biofilm-like film; and an antimicrobial polyelectrolyte layer between the biofilm-like film structure and the core structure which allows substances in the core to be released into the biofilm-like film structure while preventing the microorganisms on the film from migrating to the core material, ensuring uniform distribution of the microorganisms on the surface of the core and maintaining the microorganisms continuously exposed at the air-liquid interface.

Classes IPC  ?

• C12N 11/10 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique le support étant un hydrate de carbone
• C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p. ex. dans un gel ou dans des fibres creuses
• C12N 11/084 - Polymères comportant des unités alcool vinyliques

Abrégé

The invention provides a multi-dimensional broad-spectrum clinical in-situ testing equipment designed to evaluate the material properties of plantar soft tissue. The equipment comprises the following features: 1. A testing table with a designated area corresponding to the sole of the foot; 2. A vertical reciprocating stress-strain testing unit mounted on the testing table, for applying vertical tensile and compressive stresses to the plantar and measuring the stress-strain responses; 3. A shear stress-strain testing unit, mounted on the testing table, for applying shear stresses to the plantar and measuring the stress-strain responses; 4. A torque stress-strain detection unit, positioned on the testing stage, for applying torque to the plantar and measuring the stress-strain responses; 5. A lifting mechanism that facilitates the vertical movement of the three testing units. In conclusion, the device is capable of multi-dimensional detection of the mechanical properties of plantar and features a compact structure and easy portability.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

A polymer material, specifically a sugar backbone polymer and a synthesis method. A new type of sugar backbone polymer is prepared using a condensation and polymerization method. An addition reaction of alcohol-olefin is introduced into the synthesis of the sugar backbone polymer, to form a new functional primary sugar chain alternating polymer having alternating sugar and aliphatic units. It overcomes shortcomings of existing artificial chemical synthesis methods such as difficulty in controlling the stereoselectivity of the product, low molecular weight, cumbersome monomer preparation and few types. The molecular weight of the prepared polymer can reach 71,067 g/mol, and monomer preparation is simple.

Classes IPC  ?

• C08G 65/00 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule
• C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
• C07H 1/00 - Procédés de préparation des dérivés du sucre

Abrégé

This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that can comprise STING polypeptide, a nucleic acid encoding said STING polypeptide, a STING inhibitor, a STING activator, a STING agonist, a STING antagonist, a STING modulating molecule, or a combination thereof. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine. This disclosure is also directed to a method for treating or preventing a disease using the pharmaceutical composition. The disease can include infectious diseases caused by viruses or other pathogens, for example, influenza, rabies, or respiratory illnesses such as severe acute respiratory syndrome (SARS) caused by coronaviruses, such as MERS-CoV, SARS-CoV, and Coronavirus Disease 2019 (COVID-19) caused by the virus SARS-CoV-2 and its variants.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 9/51 - Nanocapsules
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

An anti-SARS-CoV-2 virus protein or mRNA vaccine, a preparation method therefor, and a use thereof. The protein has one or more amino acid residues added, deleted, or replaced in the amino acid sequence as shown in SEQ ID NO: 18. The nucleic acid encodes an S protein mutant. Preclinical animal test data shows that the mRNA vaccine has a good protective effect for the current variants of concern (VOC) of the SARS-CoV-2 virus and has broad clinical application prospects.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 19/00 - Peptides hybrides
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The present application relates to the technical field of biological testing, and in particular, to a biological sample testing method, system, apparatus and kit, and a use. The biological sample testing method comprises the following steps: taking a test probe and dissolving same in a solvent to prepare a test probe solution, and connecting the test probe solution to a test electrode; taking a blank solvent and connecting the blank solvent to a reference electrode; inputting power supply signals to the test electrode and the reference electrode, using a measurement module to test and record respective charging and discharging frequencies, setting a frequency difference to 0 by means of the measurement module, and disconnecting the test probe solution from the test electrode when the setting is completed; taking a biological sample to be tested, adding a test probe for specific binding, to prepare a test solution, and connecting the test probe solution to the test electrode; and inputting power supply signals to the test electrode and the reference electrode, using the measurement module to test and record respective charging and discharging frequencies, calculating a difference, and distinguishing different biological samples on the basis of the differences obtained by calculation. The method is accurate, efficient, and fast, so that the test time is greatly shortened and the test cost is saved.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12R 1/93 - Virus des animaux

Abrégé

A broad-spectrum influenza A vaccine immunogen composition and the use thereof. Provided is a nucleic acid molecule encoding an immunogenic peptide, the immunogenic peptide comprising: tandem M2e peptide fragments, an HA2 peptide fragment derived from influenza virus H7N9 subtype; a multimerized motif peptide fragment, and optionally, one or more linker peptide fragments independently located between the peptide fragments, the nucleic acid molecule comprising encoding nucleic acids of the peptide fragments. The broad-spectrum influenza A vaccine can induce organisms to generate antigen-specific immune responses, and can generate a high-titer antibody just in 14 days after the last vaccination, which can completely prevent attacks from various influenza A virus subtypes.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/12 - Antigènes viraux
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

The present invention discloses a method for preparing a highly crystalline two-dimensional MWW zeolite, comprising following steps S1-S3. Step S1 includes adding powder of two-dimensional materials into a reaction vessel, dripping an organic structure-directing agent and mixing uniformly to obtain a mixture, performing an ultrasonic treatment and centrifugation on the mixture, and collecting upper clear liquid to obtain a thin-layered dispersed solution of the two-dimensional materials after liquid phase exfoliation. Step S2 includes combing the thin-layered dispersed solution, deionized water/organic structure-directing agent, alkali metal source, and aluminum source to form a solution, slowly adding a silicon source to the solution, stirring the mixture to dissolve, and aging the mixture to obtain a sol-gel. Step S3 includes configuring the sol-gel to undergo hydrothermal crystallization to produce a reaction product, and washing, centrifuging, and drying the reaction product to obtain a highly crystalline two-dimensional MWW zeolite. In this invention, hexagonal boron nitride or molybdenum sulfide is used as a template for the epitaxial growth of two-dimensional zeolite, eliminating the need for additional organic templating agents beyond hexamethyleneimine or piperidine. This synthesis yields a two-dimensional MWW zeolite with excellent crystallinity and a high aspect ratio.

Classes IPC  ?

• C01B 39/04 - Zéolites aluminosilicates cristallinesLeurs composés isomorphesLeur préparation directeLeur préparation à partir d'un mélange réactionnel contenant une zéolite cristalline d'un autre type, ou à partir de réactants préformésLeur post-traitement utilisant au moins un agent structurant organique, p. ex. un composé d'ammonium quaternaire ionique ou un composé aminé
• B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
• B82Y 40/00 - Fabrication ou traitement des nanostructures
• B01D 53/02 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse
• B01J 29/70 - Zéolites aluminosilicates cristallinesLeurs composés isomorphes de types caractérisés par leur structure spécifique non prévus dans les groupes

Abrégé

Novel antibiotics are needed to combat the antibiotic-resistance crisis. Presented herein are machine learning-based approaches for predicting antimicrobial peptides (AMPs) within the global microbiome and leverage a vast dataset that can include metagenomes and prokaryotic genomes from environmental and host-associated habitats to create a comprehensive catalog comprising distinct, non-redundant peptides, the majority of which are novel. This platform provides insights into the evolutionary origins of peptides, including by duplication or gene truncation of longer sequences. To validate predictions, 100 AMPs were synthesized and tested against clinically relevant drug-resistant pathogens and human gut commensals, both in vitro and in vivo. Many of the synthesized peptides were active, with a large number of them targeting pathogens. The presently described computational approach can identify millions of prokaryotic AMP sequences, opening new avenues for antibiotic discovery.

Classes IPC  ?

• G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
• G16B 25/00 - TIC spécialement adaptées à l’hybridationTIC spécialement adaptées à l’expression de gènes ou de protéines
• G16B 40/20 - Analyse de données supervisée
• G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
• G16B 50/00 - TIC pour la programmation d’outils ou de systèmes de bases de données spécialement adaptées à la bio-informatique

Abrégé

The present invention relates to the technical field of wireless communications, and in particular to a compact transformer power combining network. The transformer power combining network of the present invention is composed of two primary inductors, two secondary inductors, and two resonant inductors. The primary inductors and the secondary inductors correspond to coupling coils of a transformer, and are used for realizing the functions of impedance matching, power combining, and differential-to-single-ended conversion. The resonant inductors are connected between the differential primary inductors, and are used for realizing the functions of eliminating the parasitic capacitance power loss and enhancing the electromagnetic coupling. The structure of the compact transformer power combining network is in a symmetrical form: two transformer cores are symmetrically arranged left and right. The transformer power combining network can enhance the electromagnetic induction, decreases the area required by the inductors, and reduces the circuit costs, i.e., having the advantages of low loss and low costs, and is applicable to communication applications with high carrier frequencies such as WLAN and 5G.

Classes IPC  ?

• H04B 1/04 - Circuits
• H01F 27/28 - BobinesEnroulementsConnexions conductrices
• H04L 25/02 - Systèmes à bande de base Détails

Abrégé

2.5 sampling and collection. This apparatus can be widely applied in air quality monitoring and health risk assessment.

Classes IPC  ?

• G01N 30/72 - Spectromètres de masse
• G01N 30/14 - Préparation par élimination de certains composants
• G01N 30/16 - Injection
• G01N 30/30 - Contrôle des paramètres physiques du fluide vecteur de la température
• G01N 30/06 - Préparation

Abrégé

The present invention relates to a visible-light-mediated one-step method for preparing phenol and cyclohexanone from cyclohexylbenzene (CHB). The method specifically comprises: under the irradiation of visible light, and with a hydrogen bromide solution as a catalyst and oxygen as an oxidizing agent, directly oxidizing cyclohexylbenzene in an organic solvent to break a carbon-carbon bond, so as to generate phenol and cyclohexanone. The method avoids such a process in a cyclohexylbenzene method in the prior art that cyclohexylbenzene needs to be first oxidized to obtain cyclohexylbenzene-1-hydroperoxide (1-CHBHP), then the mixture of the oxidation reaction products is treated, and then a cyclohexylbenzene peroxide is decomposed in an acidic condition to obtain phenol and cyclohexanone, and also avoids potential risks caused by the accumulation of peroxides. In addition, the method further has a great number of advantages of the operation being simple, reagents being easily available, reaction conditions being mild, easy control being achievable, the reaction being able to be scaled-up, a good selectivity being obtained, etc.

Classes IPC  ?

• C07C 37/60 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone d'un cycle aromatique à six chaînons par des réactions d'oxydation introduisant directement des groupes hydroxyle sur un groupe CH appartenant à un cycle aromatique à six chaînons avec d'autres oxydants que l'oxygène moléculaire ou des mélanges d'oxygène moléculaire et d'oxydant
• B01J 27/08 - Halogénures
• C07C 45/33 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par oxydation avec l'oxygène moléculaire de restes —CHx

Abrégé

The invention discloses a type of compound that can specifically bind to α-synuclein aggregates represented by Formula I, a radio-labelled compound thereof, a preparation method, and its use. The compound can be used as a tracer for optical imaging of α-synuclein aggregates in biological samples or in vivo (such as the brain). After radio-labelled, the compound of the invention can be used as a radio imaging tracer for PET, SPECT, and other imaging techniques to realize the detection of α-synuclein lesions by non-invasive visualization in vivo (such as the brain). The invention discloses a type of compound that can specifically bind to α-synuclein aggregates represented by Formula I, a radio-labelled compound thereof, a preparation method, and its use. The compound can be used as a tracer for optical imaging of α-synuclein aggregates in biological samples or in vivo (such as the brain). After radio-labelled, the compound of the invention can be used as a radio imaging tracer for PET, SPECT, and other imaging techniques to realize the detection of α-synuclein lesions by non-invasive visualization in vivo (such as the brain).

Classes IPC  ?

• A61K 51/04 - Composés organiques
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles

Abrégé

According to embodiments of the present disclosure, a method and apparatus for rewriting a narrative text, a device, and a medium are provided. The method includes determining a change to a sentence in a narrative text. An initial context of the sentence before the change is different from a target context of a changed sentence. The method further includes performing, based on inconsistency between a text part after the sentence in the narrative text and the target context, at least one edit operation on the text part to generate at least one edited version of the text part. The method further includes replacing the text part with an edited version in the at least one edited version to obtain a rewritten narrative text. In this way, the narrative text can be rewritten with a small number of edits while ensuring contextual coherence.

Classes IPC  ?

• G06F 40/166 - Édition, p. ex. insertion ou suppression
• G06F 40/197 - Gestion des versions
• G06F 40/30 - Analyse sémantique

Abrégé

A substance component detection apparatus and a method are provided to reduce absorption of an infrared signal by a window medium, thereby obtaining abundant fingerprint region signals. The apparatus includes: a sample pool, an infrared optical window, an infrared light source, and a detector. The infrared optical window has a first surface that faces an inner side of the sample pool and that is configured to be in contact with a to-be-detected substance, and a second surface exposed on an outer side of the sample pool. A protruding portion is formed between two adjacent grooves on the second surface, and any protruding portion has an incident surface and an emergent surface. An infrared signal emitted by the infrared light source is irradiated on the incident surface. The detector determines a component of the to-be-detected substance and/or content of the component.

Classes IPC  ?

• G01N 21/3577 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p. ex. l'eau polluée

Abrégé

A series of 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivatives represented by A series of 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivatives represented by A series of 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivatives represented by where R1 is Cl, F, Br or CH3, and R2 is 4-F, 3-Cl, 3-CF3 or 4-C(CH3)3. A pharmaceutical composition including such 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivative, or a pharmaceutically-acceptable salt thereof is provided. A preparation method of such derivative and an application of such derivative as a lead compound in the preparation of PARP14 inhibitors are further provided.

Classes IPC  ?

• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles

Abrégé

A fin field-effect transistor device with hybrid conduction mechanism, including a fin field-effect transistor, a second source region, and a second drain region; the fin field-effect transistor includes a substrate, a fin channel region, a first source region, and a first drain region; the height of the second source region is not lower than the height of the substrate between the first source region and the first drain region; the first source region, the first drain region and the second drain region are doped with first ions; the second source region is formed between the substrate and the first source region, the second drain region is formed between the substrate and the first drain region, the second source region is doped with second ions. This scheme can realize hybrid conduction of fin channel diffusion drift current and bottom channel band-to-band tunneling current, thus obtaining better ultra-steep switching characteristics.

Classes IPC  ?

• H01L 29/66 - Types de dispositifs semi-conducteurs
• H01L 29/08 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices avec des régions semi-conductrices connectées à une électrode transportant le courant à redresser, amplifier ou commuter, cette électrode faisant partie d'un dispositif à semi-conducteur qui comporte trois électrodes ou plus
• H01L 29/10 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices avec des régions semi-conductrices connectées à une électrode ne transportant pas le courant à redresser, amplifier ou commuter, cette électrode faisant partie d'un dispositif à semi-conducteur qui comporte trois électrodes ou plus
• H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée

Abrégé

A nucleic acid, a pharmaceutical composition and conjugate containing the nucleic acid, and uses thereof. In particular, the present invention relates to an siRNA, having a sense strand and an antisense strand that are complementary to each other. Nucleotides in the siRNA are each independently a modified or unmodified nucleotide. The sense strand of the siRNA contains a sequence SEQ ID NO: 1, 21 or 23 or a sequence that differs by no more than four nucleotides therefrom, and the antisense strand of the siRNA contains a sequence SEQ ID NO: 2, 22 or 24 or a sequence that differs by no more than four nucleotides therefrom. The present invention further provides a nucleic acid group comprising the nucleic acid as a first siRNA, and a second siRNA which contains a sense strand containing a sequence as shown in SEQ ID NO: 5, 7 or 43 and an antisense strand containing a sequence as shown in SEQ ID NO: 6, 8 or 44, a pharmaceutical composition and conjugate containing the nucleic acid or the nucleic acid group, and uses thereof.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

The present invention provides an imidazolium salt macrocyclic compound, and a preparation method therefor and a use thereof. Specifically disclosed are a macrocyclic compound as shown in formula (I) or a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and a use of a composition which is formed of same with a pharmaceutically acceptable carrier and capable of producing neuromuscular junction block in the preparation of muscle relaxants.

Classes IPC  ?

• C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
• C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
• A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
• A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles

Abrégé

The present invention provides alkoxy thiophene acyl arylamine compounds and a use thereof, comprising alkoxy thiophene acyl arylamine compounds having a structure as shown in formula (1), or pharmaceutically acceptable salts thereof. The alkoxy thiophene acyl arylamine compounds provided by the present invention are a class of novel sphingomyelin synthase inhibitors, which have significant inhibitory activity against SMS2, ideal physical and chemical properties such as stability and water solubility, and low potential for toxic side effects, and can be further made into a drug for preventing or treating diseases related to abnormal sphingomyelin levels.

Classes IPC  ?

• C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

A biosynthesis method for a broad-spectrum antiviral polypeptide. The present invention specifically relates to a biosynthesis method for a polypeptide HCoV-EK1 capable of inhibiting human coronavirus infections in a broad-spectrum manner. The specific process comprises: construction of an Escherichia coli genetically engineered bacterium, fermentation culture of the Escherichia coli genetically engineered bacterium, and purification of recombinant polypeptide HCoV-EK1.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to the field of biomedicine, and provides a glycopeptide molecule. According to the glycopeptide molecule, an oligosaccharide fragment is bound to an oligopeptide fragment to construct a glycopeptide molecule or glycopeptide assembly having a function of promoting osteogenesis. The glycopeptide molecule is safer, has fewer side effects, and can effectively prevent and treat osteoporosis.

Classes IPC  ?

• C07K 9/00 - Peptides ayant jusqu'à 20 amino-acides, contenant des radicaux saccharide et comportant une séquence entièrement déterminéeLeurs dérivés
• A61K 38/14 - Peptides contenant des radicaux saccharideLeurs dérivés
• A61K 31/726 - Glycosaminoglycanes, c.-à-d. mucopolysaccharides
• A61K 31/737 - Polysaccharides sulfatés, p. ex. sulfate de chondroïtine, sulfate de dermatane
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose

Abrégé

The present invention relates to a regeneration processing method for a degradable high polymer material, and a use, comprising the following steps: in a system in which an organic non-metallic catalyst and an aqueous solvent are present, performing degradation processing on a degradable high polymer material, to obtain a degradation product, the degradable high polymer material comprising one or more of a polyester material and a polycarbonate material, and the organic non-metallic catalyst being one or more selected from among a diphenyl phosphate, a binaphthyl phosphate and an organic base.

Classes IPC  ?

• C07C 51/09 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides à partir de lactones ou d'esters d'acides carboxyliques
• C07C 63/26 - Acide benzènedicarboxylique-1, 4
• C07C 68/00 - Préparation des esters de l'acide carbonique ou de l'acide formique halogéné
• C08G 63/00 - Composés macromoléculaires obtenus par des réactions créant une liaison ester carboxylique dans la chaîne principale de la macromolécule
• C08G 64/00 - Composés macromoléculaires obtenus par des réactions créant une liaison ester carbonique dans la chaîne principale de la macromolécule

Abrégé

Provided in the present invention is a center-tapped on-chip transformer having low alternating-current impedance. The center-tapped on-chip transformer comprises a center tap, a primary coil and a secondary coil, wherein the secondary coil and the primary coil are spaced apart from each other by means of a dielectric layer; and the center tap is electrically connected to the primary coil, and comprises a power line, a capacitor cell and a ground wire, the power line being electrically connected to one end of the capacitor cell, and the ground wire being electrically connected to the other end of the capacitor cell. The center-tapped on-chip transformer having low alternating-current impedance provided in the present invention reduces impedance at a center tap, and reduces parasitic inductance generated by a power line, thereby improving the performance of the transformer.

Classes IPC  ?

• H01F 29/02 - Transformateurs ou inductances variables non couverts par le groupe avec prises sur les bobines ou les enroulementsTransformateurs ou inductances variables non couverts par le groupe avec possibilités de regroupement ou d'interconnexion des enroulements
• H01F 27/29 - BornesAménagements de prises
• H01F 27/34 - Moyens particuliers pour éviter ou réduire les effets électriques ou magnétiques indésirables, p. ex. pertes à vide, courants réactifs, harmoniques, oscillations, champs de fuite

Abrégé

A gate-all-around transistor with hybrid conduction mechanism, including a GAA MOSFET, a second source region, and a second drain region. The GAA MOSFET includes a substrate, a first source region, and a first drain region. The first source region, the first drain region and the second drain region are doped with first ions, the second source region is doped with second ions. The second source region is formed between the substrate and the first source region, the second drain region is formed between the substrate and the first drain region. The height of the second source region and the second drain region are not less than the height of the substrate between the first source region and the first drain region. It can realize the hybrid conduction of the gate channel diffusion drift current and the bottom channel band tunneling current to obtain better ultra-steep switching characteristics.

Classes IPC  ?

• H01L 27/06 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des éléments de circuit passif intégrés avec au moins une barrière de potentiel ou une barrière de surface le substrat étant un corps semi-conducteur comprenant une pluralité de composants individuels dans une configuration non répétitive
• H01L 21/8249 - Technologie bipolaire et MOS
• H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
• H01L 29/16 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, mis à part les matériaux de dopage ou autres impuretés, seulement des éléments du groupe IV de la classification périodique, sous forme non combinée
• H01L 29/20 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés AIIIBV
• H01L 29/22 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés AIIBVI
• H01L 29/423 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative ne transportant pas le courant à redresser, à amplifier ou à commuter
• H01L 29/66 - Types de dispositifs semi-conducteurs
• H01L 29/739 - Dispositifs du type transistor, c.à d. susceptibles de répondre en continu aux signaux de commande appliqués commandés par effet de champ
• H01L 29/775 - Transistors à effet de champ avec un canal à gaz de porteurs de charge à une dimension, p.ex. FET à fil quantique
• H01L 29/786 - Transistors à couche mince

Abrégé

The invention relates to precision measurement technology, specifically a high-sensitivity three-dimensional topography recovery method using dual-channel differentiation. Enhancing a traditional microscopic imaging system, a beam splitter is added between the objective lens and tube lens. This creates an additional light path equipped with a tube lens and camera identical to the original but with a slightly different distance to the camera. During axial scanning of the object, focusing evaluation function curves for each pixel are calculated from images captured by both cameras. The curves from the two cameras show more significant changes near the optimal focusing depth, improving system sensitivity. This method enhances sensitivity by hardware-fixed differentiation of the focusing evaluation function, while maintaining high scanning efficiency and flexible configuration.

Classes IPC  ?

• H04N 23/67 - Commande de la mise au point basée sur les signaux électroniques du capteur d'image
• G02B 21/00 - Microscopes

Abrégé

The present invention relates to an antibody against a hepatitis B surface antigen (HBsAg) and an antigen-binding fragment thereof, and methods for preparing and using the antibody and the antigen-binding fragment thereof. The present invention further relates to bispecific antibodies that specifically bind to different epitopes on HBsAg. The antibodies are derived from persons inoculated with hepatitis B vaccines and persons having recovered from hepatitis B infections, show superior effects in recognizing different hepatitis B surface antigens, and have greater advantages in neutralizing hepatitis B virus mutants and reducing hepatitis B mutant antigens.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux

Abrégé

A sustained-release gel with insoluble salt as pH adjuster, and its preparation method and application are disclosed. The sustained-release gel is obtained by dissolving polymer in an aqueous solvent, followed by blending and compounding the alkaline inclusion and the insoluble salt crystalline powder. The insoluble salt is at solid state and thus has thus a large amount as the reservoir of the pH adjuster. The preparation is injectable, can be converted into gel state after being injected into organism, and realizes the sustained release of the inclusion at the injection site. The presence of the insoluble salt reduces the solubility of the inclusion in the gel by releasing the free salt sustainably and thus adjusting the pH inside the gel in a sustained manner. The burst release of the inclusion out of the gel is significantly alleviated.

Classes IPC  ?

• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 31/131 - Amines, p. ex. amantadine acycliques
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/245 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p. ex. procaïne, novocaïne
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/455 - Acide nicotinique, c.-à-d. niacineSes dérivés, p. ex. esters, amides
• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

A stable RNA molecule prepared in vitro and a use thereof in preparation of an in-vivo in-situ CAR treatment product, wherein mRNA is redesigned, and protective RNA secondary structures are added to two ends of the mRNA to protect the mRNA from being cut by an RNA exonuclease, thereby improving the stability of RNA; moreover, IRES is used for replacing a 5'-terminal m7G cap structure to recruit ribosomes to start protein translation, so that the mRNA retains a translation function, the stability of the mRNA is improved, and there is no need to add caps and tails to the two ends of the mRNA, thereby greatly reducing the preparation cost of the mRNA, and improving the in-vitro production efficiency of the mRNA. Besides, on this basis, a polycistronic RNA platform is constructed, IRESs are used for expressing a plurality of protein sequences, respectively, making up for the deficiency that monocistronic RNA technology cannot be used to simultaneously express a plurality of functional proteins.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
• C12N 15/65 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression utilisant des marqueurs
• A61K 39/135 - Virus de la fièvre aphteuse
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

bcbdbb of the polymer B. The hydrogel has a relatively good biological safety and can be used in the preparation of medical preparations, etc.

Classes IPC  ?

• C08L 77/04 - Polyamides dérivés des acides alpha-aminocarboxyliques
• C08J 3/075 - Gels macromoléculaires

Abrégé

Relating to the technical field of biological medicine, particularly the use of a kinase domain M7CK of TRPM7 in the preparation of a drug for treating Alzheimer's disease. The over-expression of M7CK can relieve cognitive impairment of a mouse model with AD by increasing an MMP14 phosphorylation level, improving learning and memory ability, increasing synaptic density and density of a presynaptic vesicle protein synaptophysin and a postsynaptic density protein PSD-95, promoting degradation of Aβ in soluble and insoluble components, and reducing accumulation of Aβ amyloid plaques. Therefore, the kinase domain of TRPM7 provided has a great application prospect in gene therapy of a patient with Alzheimer's disease

Classes IPC  ?

• A61K 38/45 - Transférases (2)
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

A Gate All Around (GAA) transistor device having a U-shaped gate at the bottom, comprising: a substrate (101), a first source region (109), a first drain region (110), a first control gate, and a first channel layer, wherein first ions are doped in the first source region (109) and the first drain region (110), the first channel layer is the channel layer most proximate to the substrate, and the first control gate is the control gate most proximate to the substrate; a second source region (107) formed between the substrate (101) and the first source region (109), and a second drain region (108) formed between the substrate (101) and the first drain region (110), wherein first ions are doped in the second drain region (108), second ions are doped in the second source region (107), and the type of the first ions is different from that of the second ions; the thickness of the first control gate in a second direction is greater than that of other control gates in the second direction; in the second direction, first surfaces of the second source region (107) and the second drain region (108) are not higher than the bottom surface of the first channel layer, and second surfaces are not lower than the surface of the substrate (101) between the second source region (107) and the second drain region (108). The technical solution solves the problem of direct tunneling of a source and a drain in the GAA transistor device while preventing leakage of a bottom parasitic channel.

Classes IPC  ?

• H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée
• H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
• H01L 29/423 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative ne transportant pas le courant à redresser, à amplifier ou à commuter

Abrégé

Provided in the present invention is a gate-all-around transistor based on a hybrid conduction mechanism, the gate-all-around transistor comprising: a gate-all-around MOSFET device, which comprises a substrate, a first source region, a first drain region, a first gate dielectric layer, and a gate-all-around channel control gate, wherein the first source region and the first drain region are doped with first ions; a second source region, which is formed between the substrate and the first source region, and a second drain region, which is formed between the substrate and the first drain region, wherein the height of the second source region and the height of the second drain region are not less than the height of the substrate between the first source region and the first drain region, the second drain region is doped with the first ions, and the second source region is doped with second ions; and a bottom control gate, wherein the bottom control gate covers the surface of the gate dielectric layer on the substrate, the gate-all-around channel control gate covers the surface of the bottom control gate, and the difference between a work function of the bottom control gate and that of the gate-all-around channel control gate is greater than 0.5 eV. This technical solution solves the problem of it not being possible to highlight the characteristic of an ultra-steep subthreshold swing being less than 60 mV/dec in a bottom subthreshold region.

Classes IPC  ?

• H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée
• H01L 21/336 - Transistors à effet de champ à grille isolée
• H01L 29/08 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices avec des régions semi-conductrices connectées à une électrode transportant le courant à redresser, amplifier ou commuter, cette électrode faisant partie d'un dispositif à semi-conducteur qui comporte trois électrodes ou plus

Abrégé

A use of a recombinant expressed protein in prevention and/or treatment of a respiratory disease. Provided is a use of two recombinant expressed proteins in preparation of a drug for prevention and/or treatment of a respiratory disease. The respiratory disease is caused by influenza A virus infection or co-infection of influenza A virus and novel coronavirus. GRFT has an amino acid sequence shown in SEQ ID NO: 1, and GL25E has an amino acid sequence shown in SEQ ID NO: 2. The recombinant protein GRFT and fusion protein GL25E can effectively inhibit the influenza A virus infection, wherein GL25E is formed by coupling an EK1 polypeptide on the basis of GRFT, the recombinant protein GRFT and fusion protein GL25E have good inhibitory activity against influenza A virus, also have good inhibitory activity against the co-infection of influenza virus and novel coronavirus, and can be used in preparation of drugs for prevention and/or treatment of respiratory diseases caused by influenza virus and the co-infection of influenza virus and coronavirus.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

The present application provides a method for preparing a deuterated chemical by means of a deuteration reaction of a carbon-hydrogen bond with a deuterium gas under the catalysis of an alkali, wherein in the presence of a catalyst, a deuterium gas is added into a compound containing a carbon-hydrogen bond for a deuteration reaction so as to generate a deuterated compound. A deuterium gas is used as a deuterium source, such that multiple water separation operations, tedious steps and the wasting of energy caused by usage of a large amount of deuterium oxide as a deuterium source are avoided. Moreover, a cheap and easily available alkali metal compound is used for replacing an expensive transition metal catalyst and a complex-structure ligand as a catalyst for a deuteration reaction, and the alkali metal compound has the advantages of a low cost, a good compatibility with functional groups of a substrate and a high deuteration rate. The present application provides a new, low-cost, green and efficient deuteration method, which has a high application value.

Classes IPC  ?

• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques

Abrégé

Disclosed in the present invention are a split-gate silicon carbide device with a buried field-limiting ring and a method for preparing same. Said device sequentially comprises, from bottom to top, a drain electrode, a drift region, and a P-well region, and further comprises a U-shaped groove that penetrates through the P-well region; a buried P-type field-limiting ring, formed on the periphery of the bottom of the groove; a P+region and an N+ region, connected to each other and formed on the P-well region on both sides of the groove; a gate electrode, formed in the groove and comprising a transistor gate electrode located on the outer side and a field-limiting ring contact bolt located in the middle area, the transistor gate electrode being wrapped by an oxide layer, the top of the field-limiting ring contact bolt being connected to a source electrode, and the bottom of the field-limiting ring contact bolt being connected to the buried P-type field-limiting ring; and the source electrode, covering the surface of the device, wherein the P-type field-limiting ring is connected to the source electrode by means of the field-limiting ring contact bolt to realize a potential equal to the source electrode, thereby reducing the electric field in the oxide layer of the gate electrode on both sides of the groove, and enabling a depletion region of the device in a reverse bias state to be limited outside channel regions on both sides.

Classes IPC  ?

• H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
• H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée
• H01L 21/336 - Transistors à effet de champ à grille isolée

Abrégé

Use of an anti-inflammatory drug in resisting CRS caused by CART therapy. Specifically, in CART therapy, the use of an anti-inflammatory drug can effectively reduce various side effects of immunotherapy such as CART therapy, TCRT therapy, and antibody therapy, such as weight loss, fever and other CRS-related symptoms.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/265 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbonique, thiocarboniques, thiocarboxyliques, p. ex. acide thio-acétique, acide xanthogénique, acide trithiocarbonique
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 37/02 - Immunomodulateurs

Abrégé

A focused ultrasound treatment system has: a focused ultrasound unit configured to emit focused ultrasound waves to a focal region to perform treatment; an ultrasound imaging unit configured to, after treatment emit imaging ultrasonic waves to an imaging region and receive corresponding echoes, and image a corresponding vascular blood flow image on the basis of the echo; a region planning and parameter adjustment unit configured to re-delineate a focal region on the basis of the vascular blood flow image and to re-adjust a treatment parameter of the focused ultrasound unit so as to be used to next treat the re-delineated focal region. The imaging region contains the focal region.

Classes IPC  ?

• A61N 7/02 - Hyperthermie localisée par ultrasons
• A61B 8/06 - Mesure du débit sanguin
• A61B 8/08 - Applications cliniques
• A61N 7/00 - Thérapie par ultrasons

Abrégé

A primer composition, a kit and a method for detecting polymorphic STR markers based on capillary electrophoresis and applications thereof are provided, which are used to simultaneously amplify 13 STR loci on cattle genome. The primer composition includes one or more pairs of primers with sequences as shown in SEQ ID NO: 1˜26. Developmental validation indicated that the kit is of high sensitivity, fine specificity, strong stability and high accuracy. This provides an effective tool for species identification, individual identification and parental analysis of cattle samples in civil disputes and illegal crimes.

Classes IPC  ?

• C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes

Abrégé

Provided is a long-acting method for a coronavirus polypeptide fusion inhibitor. The method comprises coupling an IgG Fc binding peptide to a coronavirus polypeptide therapeutic agent, wherein the coronavirus polypeptide therapeutic agent comprises an amino acid sequence selected from SEQ ID NOs: 1-3, or a variant thereof having substitution, insertion, deletion or addition of one or more amino acids, and the IgG Fc binding peptide comprises an amino acid sequence of SEQ ID NO: 4, or a variant thereof having substitution, insertion, deletion or addition of one or more amino acids. By means of the method, the coronavirus polypeptide therapeutic agent can be long-acting or the effect of the coronavirus polypeptide therapeutic agent is improved.

Classes IPC  ?

• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• C07K 19/00 - Peptides hybrides
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

Provided in the present invention are a β-catenin/BCL9 protein-protein interaction inhibitor, a preparation method therefor and the use thereof. Specifically, the inhibitor provided by the present invention comprises at least one compound or a derivative of said at least one compound. The compound has a novel structure, the structural formula of the compound being any one of formula (I), formula (II), formula (III), formula (IV) and formula (V). The inhibitor of the present invention has the advantages of high pharmacological activity, good safety, good water solubility, good anti-tumor cell proliferation activity, stable in-vitro liver microsome metabolism, etc.

Classes IPC  ?

• C07D 217/06 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle contenant l'azoteAlkylène-bis-isoquinoléines avec l'atome d'azote du cycle acylé par des acides carboxyliques, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
• A61K 31/47 - QuinoléinesIsoquinoléines
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed are a novel nanobody (Nb) targeting a tissue factor (TF), and a nanobody-drug conjugate (NDC) and a preparation method therefor and use thereof. The monoclonal Nb and the corresponding NDC of the present invention can effectively and specifically bind to a purified TF protein and TFs on the surface of tumor cells with multiple TF abnormal expressions, have high affinity and low immunogenicity, and have significant in vivo and in vitro anti-tumor effects.

Classes IPC  ?

• C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
• C07K 16/46 - Immunoglobulines hybrides
• C07K 19/00 - Peptides hybrides
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention provides a pre-embedding agent using organic sulfinate as a framework for pre-embedding lithium or sodium, a pre-embedded lithium positive electrode, a pre-embedded sodium positive electrode, a secondary battery, and a method for pre-embedding lithium or sodium using the pre-embedding agent. The pre-embedding agent of the present invention has a high specific capacity, excellent stability, is free of residues, has excellent compatibility with a battery system, and can be well applied to lithium- or sodium-ion secondary batteries. A pre-embedding process of the method for pre-embedding lithium or sodium of the present invention is safe and convenient, the process is simple, the costs are low, and large-scale production can be achieved.

Classes IPC  ?

• H01M 10/058 - Structure ou fabrication

Abrégé

Disclosed are a new nanobody (Nb) targeting a tissue factor (TF) and a nanobody-drug conjugate (NDC), a preparation method therefor and the use thereof. The monoclonal nanobody and the corresponding NDC can efficiently and high-specifically bind to a purified TF protein and a TF on the surface of various TF abnormally expressed tumor cells, have a high affinity and a low immunogenicity, and have a significant anti-tumor effect in vivo and in vitro.

Classes IPC  ?

• C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
• C07K 7/02 - Peptides linéaires contenant au moins une liaison peptidique anormale
• A61P 35/00 - Agents anticancéreux
• C07K 16/46 - Immunoglobulines hybrides
• C07K 19/00 - Peptides hybrides
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

Provided are a protein or mRNA vaccine against novel coronavirus and a preparation method and a use thereof. The protein has increase, deletions or substitutions of one or more amino acid residues on an amino acid sequence as shown in SEQ ID NO: 59. Also provided is a corresponding nucleic acid that encodes an S protein mutant. Preclinical animal test data shows that the mRNA vaccine has a good protection effect on current mainstream variants of concern (VOC), good stability, and long-lasting efficacy, and has a wide clinical application prospect.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

2222O material, the catalytic activity of the heterostructure is greatly increased, and the water photolysis efficiency is relatively high.

Classes IPC  ?

• B01J 27/24 - Composés de l'azote
• C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac

Abrégé

The present invention relates to a photo-response detector, in particular to a ferroelectric field modulated positive and negative photo-response detector, a preparation method and application thereof. The ferroelectric field modulated positive and negative photo-response detector includes a substrate, a gate electrode, a ferroelectric layer, a low-dimensional semiconductor and a source-drain electrode. A pair of gate electrodes are provided and fixedly arranged on the substrate at intervals. The ferroelectric layer is fixedly arranged on the substrate and completely covers the gate electrode. The low-dimensional semiconductor is fixedly arranged on the ferroelectric layer. The source-drain electrode includes a source electrode and a drain electrode separately arranged on two sides of the low-dimensional semiconductor and fixedly arranged on the ferroelectric layer.

Classes IPC  ?

• H01L 29/51 - Matériaux isolants associés à ces électrodes
• G06N 3/06 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone
• H01L 31/113 - Dispositifs sensibles au rayonnement infrarouge, visible ou ultraviolet caractérisés par un fonctionnement par effet de champ, p.ex. phototransistor à effet de champ à jonction du type conducteur-isolant-semi-conducteur, p.ex. transistor à effet de champ métal-isolant-semi-conducteur
• H01L 31/18 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives

Abrégé

A segmented aperture imaging/positioning method of a multi-rotor unmanned aerial radar. A target echo is acquired based on an unmanned aerial vehicle-borne synthetic aperture radar system. An echo signal estimated from the motion state of a manoeuvring platform is segmented. Motion compensation is performed on each echo signal segment. A two-dimensional spectrum is obtained by performing a two-dimensional Fourier transform on each compensated echo signal segment. A series inversion method to decompose the two-dimensional spectrum is used to obtain a phase filter of each segment. The two-dimensional spectrum of each segment is multiplied by the phase filter, and an image of each segment is obtained by performing two-dimensional inverse Fourier transform on the two-dimensional spectrum. A full-aperture imaging result is obtained by performing geometric corrections on the images and splicing them. The trajectory of each segment of the platform is spliced to obtain complete trajectory coordinates of the platform.

Classes IPC  ?

• G01S 13/90 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation utilisant des techniques d'antenne synthétique

Abrégé

A method for preparing a wafer-scale two-dimensional (2D) material array includes the following steps. Water and alcohol solvent are mixed to obtain a mixed solution. A polydimethylsiloxane (PDMS) stamp with micro posts is prepared. A monolayer two-dimensional transition metal dichalcogenides (2D-TMDs) film is continuously grown on a growth substrate. The PDMS stamp is put upside down to allow the micro posts to adhere to the monolayer 2D-TMDs film, so as to obtain a PDMS stamp-2D-TMDs film-growth substrate combination. The PDMS stamp-2D-TMDs film-growth substrate combination is immersed in the mixed solution to separate the monolayer 2D-TMDs film from the growth substrate. A portion of the monolayer 2D-TMDs film which is not in contact with upper surfaces of the micro posts is removed to obtain a patterned 2D-TMDs film. The patterned 2D-TMDs film is transferred to a target substrate to obtain the wafer-scale 2D material array.

Classes IPC  ?

• H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
• H01L 29/786 - Transistors à couche mince

Abrégé

The present application relates to a brain age prediction method based on dual-modality imaging, comprising dual-modality feature fusion. The dual-modality comprises both MRI medical imaging and PET medical imaging; and the feature fusion is obtained on the basis of a 3D convolutional neural network method, and comprises the following steps: extracting features of PET and MRI images by using two 3D convolutional neural networks as backbone networks; concatenating, in a channel dimension, the features of the MRI and PET images extracted by the two backbone networks, and then inputting same into squeeze-and-excitation networks; and multiplying an output result of an excitation part by an original feature map to obtain features of fused channel attention information, and obtaining a fused feature map of dual-modality features.

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• G06V 10/80 - Fusion, c.-à-d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06N 3/0464 - Réseaux convolutifs [CNN, ConvNet]
• G06N 3/0495 - Réseaux quantifiésRéseaux parcimonieuxRéseaux compressés
• G06N 3/047 - Réseaux probabilistes ou stochastiques
• G06N 3/048 - Fonctions d’activation
• G06N 3/08 - Méthodes d'apprentissage
• G06N 3/084 - Rétropropagation, p. ex. suivant l’algorithme du gradient

Abrégé

A protein or mRNA vaccine against novel coronavirus and a preparation method therefor and a use thereof. The protein has addition, deletion or substitution of one or more amino acid residues in an amino acid sequence shown in SEQ ID NO: 2. A nucleic acid encodes an S protein mutant. The preclinical animal test data of the mRNA vaccine shows that the mRNA vaccine has a good protection effect against current novel coronavirus mainstream variants of concern (VOCs).

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire

Abrégé

The invention discloses a method and an apparatus for trapping and manipulating particles, relating to the field of acoustic manipulation. The invention discloses a photoacoustic tweezers, which use bimodal transducer generate a weak acoustic wave and a strong acoustic wave. The strong acoustic wave behaves as an effective gain medium to amplify the acoustic radiation force of this weak acoustic wave. After an interference of the strong acoustic wave and the weak acoustic wave, an amplified trapping force is produced for achieving the trapping and manipulation of particles. The invention can manipulate several particles simultaneously in high throughput and particles of various sizes ranging from 1 μm to 1 mm. The invention can form reconfigurable acoustic fields which permits versatile and selective manipulation with no need of complicated acoustic arrays. The invention is a versatile, biocompatible, selective and high-throughput manipulation method.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 15/1404 - Manipulation du flux, p. ex. focalisation hydrodynamique
• G01N 15/1409 - Manipulation des échantillons, p. ex. injection des échantillons

Abrégé

Implementations of the present disclosure provide a method, a device, and an apparatus for verifying a veracity of a statement, and a medium. In One method, includes: training data including a statement, an evidence set, and a label are acquired. The statement is divided into a plurality of phrases based on a grammatical analysis of the statement. A phrase verification model is trained based on the training data and the plurality of phrases, so that the phrase verification model determines a plurality of phrase veracities of the plurality of phrases respectively based on the evidence set. A statement verification model is trained based on the training data and the plurality of phrases, so that the statement verification model determines a statement veracity of the statement based on the evidence set, where the plurality of phrase veracities provide an interpretation for the statement veracity.

Classes IPC  ?

• G06N 3/096 - Apprentissage par transfert
• G06F 40/166 - Édition, p. ex. insertion ou suppression
• G06F 40/253 - Analyse grammaticaleCorrigé du style
• G06F 40/289 - Analyse syntagmatique, p. ex. techniques d’états finis ou regroupement
• G06N 3/045 - Combinaisons de réseaux

Abrégé

The present disclosure provides naphthalenesulfonyl compounds, preparation methods and application thereof. Specifically disclosed is a compound of formula (I) or a salt thereof, which serves as a specific derivatization reagent capable of reacting with hydroxyl and amino groups. The compound features simple synthesis, high reactivity, and ready availability at low cost, and is capable of improving chromatographic separation behaviors of target compounds and enhancing the detection sensitivities of these compounds. The present disclosure provides naphthalenesulfonyl compounds, preparation methods and application thereof. Specifically disclosed is a compound of formula (I) or a salt thereof, which serves as a specific derivatization reagent capable of reacting with hydroxyl and amino groups. The compound features simple synthesis, high reactivity, and ready availability at low cost, and is capable of improving chromatographic separation behaviors of target compounds and enhancing the detection sensitivities of these compounds.

Classes IPC  ?

• C07C 309/51 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné contenant des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au squelette carboné au moins un des atomes d'azote faisant partie de l'un des groupes X étant un hétéro-atome, Y étant un atome quelconque
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 309/88 - Halogénures d'acides sulfoniques ayant des groupes halogénosulfonyle liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné contenant des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au squelette carboné
• G01N 30/02 - Chromatographie sur colonne
• G01N 30/06 - Préparation
• G01N 30/08 - Préparation par enrichissement

Abrégé

The present invention provides a small molecule TNF-α inhibitor STU104 and a preparation method and use thereof, wherein an absolute configuration of an optical isomer (R)-STU104 is identified, especially it has found use of STU104 for treatment of autoimmune inflammatory diseases mediated due to TNF-α overexpression including ulcerative colitis, Crohn's disease, rheumatoid arthritis, osteoarthritis, alopecia areata, Sjogren's syndrome, lupus erythematosus, dermatomyositis, etc. The present invention has broad clinical therapeutic significance.

Classes IPC  ?

• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• C07C 45/65 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par des réactions ne créant pas de groupe C=O par élimination d'atomes d'hydrogène ou de groupes fonctionnelsPréparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par des réactions ne créant pas de groupe C=O par hydrogénolyse de groupes fonctionnels
• C07C 49/755 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle contenant des groupes éther, des groupes , des groupes ou des groupes un groupe cétone faisant partie d'un système cyclique condensé de deux ou trois cycles, un des cycles au moins étant un cycle aromatique à six chaînons
• C07C 315/04 - Préparation de sulfonesPréparation de sulfoxydes par des réactions n'impliquant pas la formation de groupes sulfone ou sulfoxyde

Abrégé

Organic intermediate synthesis, and provides a method for light-promoted oxidation of a compound containing a saturated carbon-hydrogen bond, comprising mixing a compound containing a saturated carbon-hydrogen bond with a catalyst, and oxidizing the compound containing a saturated carbon-hydrogen bond in an oxygen or air atmosphere at a temperature of 20° C. to 100° C. under light irradiation to generate an oxidation product. A method for the light-promoted direct oxidation of a compound containing a saturated carbon-hydrogen bond, which only requires a relatively low temperature to be carried out, has good compatibility with functional groups, short reaction time, high reaction efficiency, low reaction costs, high added value, simple operation and good safety, and is a mild, green and environmentally friendly oxidation method.

Classes IPC  ?

• C07C 27/12 - Procédés impliquant la production simultanée de plusieurs classes de composés contenant de l'oxygène par oxydation d'hydrocarbures avec l'oxygène
• C07C 29/50 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par des réactions d'oxydation avec formation de groupes hydroxyle uniquement par l'oxygène moléculaire
• C07C 45/32 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par oxydation avec l'oxygène moléculaire

Abrégé

A full continuous synthesis method of metronidazole is provided. An aqueous glyoxal solution, an aqueous acetaldehyde solution and aqueous ammonia are mixed and reacted to produce a 2-methylimidazole-containing reaction mixture, which is mixed with a nitric acid solution and then reacted in the presence of concentrated sulfuric acid to obtain a 2-methyl-5-nitroimidazole-containing reaction mixture. The 2-methyl-5-nitroimidazole-containing reaction mixture is divided by a splitter, such that one part is used to replace concentrated sulfuric acid, and the other part is mixed with formic acid, and undergoes a ring-opening reaction with ethylene oxide to obtain a metronidazole solution. The metronidazole solution is adjusted to pH 2-6 and filtered to obtain a filtrate, which is adjusted to pH 8-14 and filtered to obtain a crude product. The crude product is subjected to decoloring, crystallization, filtration and drying to obtain pure metronidazole with a purity greater than 99.9%.

Classes IPC  ?

• C07D 233/94 - Radicaux nitro liés en position 4 ou 5 avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre, liés aux autres chaînons du cycle
• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés

Abrégé

A full-color display textile (6), comprising a plurality of pixel points (7) of different colors, the colors of the pixel points (7) comprising red, orange, yellow, green, cyan, blue, purple or white. Each pixel point (7) is formed by overlapping warp electroluminescent display active fibers (3) and weft conductive fibers (1), the warp electroluminescent display active fibers (3) sequentially comprising flexible conductive fibers, an electroluminescent active layer and a resin protective layer from inside to outside. In the electroluminescent active layer, color particles are added to an electroluminescent material so as to regulate the colors of emitted lights, the addition amount of the color particles being 0.5-10 wt% of the electroluminescent material. Using the principle of matching a light excitation material and a light conversion material can prepare electroluminescent display active fibers of different colors, which can be further assembled into a color display textile. A circuit is used to control the different pixel points (7) so as to display color patterns, and the obtained textile has the advantages of excellent flexibility, breathability and the like.

Classes IPC  ?

• D03D 15/547 - Tissus caractérisés par la matière, la structure ou les propriétés des fibres, des filaments, des filés, des fils ou des autres éléments utilisés en chaîne ou en trame caractérisés par les propriétés des filés ou des fils à fonctions optiques autres que la couleur, p. ex. comportant des fibres émettrices de lumière
• D02G 3/44 - Filés ou fils caractérisés par la destination pour laquelle ils ont été conçus
• H05B 33/10 - Appareils ou procédés spécialement adaptés à la fabrication des sources lumineuses électroluminescentes
• C09K 11/00 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes
• G02F 1/1514 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur un effet électrochromique caractérisés par le matériau électrochromique, p. ex. par le matériau électro-déposé

Abrégé

A gas flow conversion apparatus for a silicon carbide horizontal epitaxial furnace, comprising a gas intake mechanism, a primary dispersion mechanism, and a hole plate assembly. A gas discharge end of the gas intake mechanism is provided with a first vent hole. The primary dispersion mechanism is fixedly mounted at the gas discharge end of the gas intake mechanism. A plurality of gas guide hole assemblies in communication with the first vent hole are provided in the primary dispersion mechanism. The hole plate assembly is fixedly mounted at an end of the primary dispersion mechanism away from the first vent hole. The hole plate assembly is used to disperse a gas flow in the gas guide hole assemblies and then discharge same. Flow guide directions of the first vent hole, the gas guide hole assemblies, and the hole plate assembly are all arranged perpendicular to a gas flow direction in the gas intake mechanism.

Classes IPC  ?

• C30B 25/14 - Moyens d'introduction et d'évacuation des gazModification du courant des gaz réactifs
• C30B 29/36 - Carbures

Abrégé

A method for on-line continuous recovery of excess nitric acid in nitration reaction is provided. Nitration reaction liquid and nitrogen gas are simultaneously conveyed to a mixer, mixed and transferred to a temperature-controlled corrosion-resistant column for on-line continuous evaporation, where the nitration reaction liquid enters the temperature-controlled corrosion-resistant column from a top end, and the waste gas and excess nitric acid are discharged from a top port of the temperature-controlled corrosion-resistant column, and nitric acid is recovered. The nitric acid-free liquid is discharged from a bottom end of the temperature-controlled corrosion-resistant column by a pump.

Classes IPC  ?

• C01B 21/46 - PurificationSéparation
• B01D 1/00 - Évaporation
• B01D 5/00 - Condensation de vapeursRécupération de solvants volatils par condensation

Abrégé

A method for evading a preexisting anti-PEG antibody in a human body, and the use of a PEGylated nano-carrier containing terminal hydroxyl in the preparation of a drug for evading a preexisting anti-PEG antibody in the human body. A PEGylated nano-carrier and nano-preparation containing terminal hydroxyl are included. The PEGylated nano-carrier and nano-preparation containing terminal hydroxyl have low binding with the preexisting anti-PEG antibody in the human body, and can thus evade being quickly cleared from the blood of the human body, so as to have a better treatment effect. In addition, by means of evading binding of the PEGylated nano-carrier and the nano-preparation containing terminal hydroxyl to the preexisting anti-PEG antibody in human blood, complement activation can be reduced, and side effects such as clinical injection reaction are reduced.

Classes IPC  ?

• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres

Abrégé

Disclosed are a small molecule inhibitor for β-catenin/BCL9 protein-protein interaction and a use thereof. Specifically provided are a compound as represented by formula (I), or an isomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the definitions of ring A, X, R1, R2, and R3 are as described in the description. The compound as represented by formula (I) has good β-catenin/BCL9 protein-protein affinity, good anti-tumor activity, and good application prospects.

Classes IPC  ?

• C07D 211/22 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons simples par des atomes d'oxygène
• C07D 409/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 211/96 - Atome de soufre
• C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61P 35/00 - Agents anticancéreux
• A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène

Abrégé

The invention discloses an apparatus and a method for capturing and manipulating particles, relating to the field of acoustic manipulation. In view of the problems in the prior art that can't achieve a contactless, versatile, selective, and universal manipulation method for particles, the present application provides photoacoustic tweezers, which uses a photoacoustic transducer unit and an electroacoustic transducer unit to form a bimodal transducer, generates a weak acoustic wave and strong acoustic wave respectively through signal excitation. The strong acoustic wave behaving as a gain medium, amplifies the acoustic radiation force of the weak acoustic wave. The invention enables contactless and label-free selective capture and manipulation of particles. Further, the amplified acoustic radiation force enhances biocompatibility by requiring lower optical powers than alternative optical methods.

Classes IPC  ?

• G02B 21/32 - Micromanipulateurs combinés par construction avec des microscopes
• G10K 15/02 - Synthèse des ondes sonores

Abrégé

Provided in the present invention is a gate-all-around transistor based on a hybrid conduction mechanism. The transistor comprises a gate-all-around MOSFET device, a second source region and a second drain region, wherein the gate-all-around MOSFET device comprises a substrate, a first source region and a first drain region; the first source region and the first drain region are doped with first ions; the second source region is formed between the substrate and the first source region, the second drain region is formed between the substrate and the first drain region, and the height of the second source region and the height of the second drain region are not lower than the height of the substrate between the first source region and the first drain region; and the second drain region is doped with the first ions, and the second source region is doped with second ions. The technical solution solves the problem of current leakage in a bottom parasitic channel of a gate-all-around MOSFET device; moreover, by means of additionally providing the second source region and the second drain region, which is equivalent to connecting a tunneling field-effect transistor (TFET) device structure in parallel at the bottom of a conventional gate-all-around MOSFET device, hybrid conduction of a diffusion drift current in a gate-all-around channel and a band-to-band tunneling current in a bottom channel can be realized, thereby obtaining a better ultra-steep switching characteristic.

Classes IPC  ?

• H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée
• H01L 21/336 - Transistors à effet de champ à grille isolée
• H01L 29/423 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative ne transportant pas le courant à redresser, à amplifier ou à commuter

Abrégé

Provided in the present invention is a fin field-effect transistor device based on a hybrid conduction mechanism. The device comprises a fin field-effect transistor, a second source region and a second drain region, wherein the fin field-effect transistor comprises a base, a fin channel region, a first source region and a first drain region; the height of the second source region is not lower than the height of the base between the first source region and the first drain region; the first source region and the first drain region are doped with first ions; and the second source region is formed between the base and the first source region, the second drain region is formed between the base and the first drain region, and the second drain region and the second source region are respectively doped with the first ions and second ions. By means of the solution, the problem of current leakage occurring at the bottom of a fin field-effect transistor is solved, and additionally arranging a second source region and a second drain region is equivalent to connecting a tunnelling field-effect transistor device structure in parallel at the bottom of the fin field-effect transistor, such that a fin channel diffusion drift current and a bottom channel band-to-band tunnelling current can be conducted in a hybrid mode, thereby obtaining better super-steep switch characteristics.

Classes IPC  ?

• H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée
• H01L 21/336 - Transistors à effet de champ à grille isolée
• H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices

Abrégé

The present invention relates to a method for extracting intracellular polymer PHA, the extraction method comprising the following steps: centrifuging sludge containing intracellular PHA to obtain a supernatant and precipitated sludge; adding a hydrochloric acid solution to the obtained precipitated sludge, then adding a sodium hypochlorite solution, uniformly mixing the mixture, and then adding a sodium hydroxide solution to adjust the pH to 7 or more; and then performing centrifugal separation again to obtain a PHA-containing solid product and a supernatant containing other cytoplasm, wherein the resulting PHA-containing solid product is a PHA crude product. Compared with the prior art, according to the extraction method provided in the present invention, the PHA is directly extracted from the sludge containing intracellular PHA by means of acid + sodium hypochlorite without undergoing pretreatments such as freeze drying and thermal cracking, and the purity and extraction rate of the obtained PHA product are high; and no halogenated organic solvent is used, and surfactants in wastewater do not need to be removed. The method has the advantages of low cost, high efficiency and simple operation.

Classes IPC  ?

• C12P 7/00 - Préparation de composés organiques contenant de l'oxygène
• C02F 11/00 - Traitement des boues d'égoutDispositifs à cet effet
• C08G 63/00 - Composés macromoléculaires obtenus par des réactions créant une liaison ester carboxylique dans la chaîne principale de la macromolécule

Abrégé

Disclosed in the present invention is a preparation method for a tetra-substituted allenoic acid compound based on a palladium catalytic system, that is, a highly optically active allenoic acid compound having axial chirality is directly constructed in one step by reacting tertiary propargyl alcohol, carbon monoxide and water in an organic solvent under the action of a palladium catalyst, a chiral bisphosphine ligand, an organophosphoric acid, and an organic additive, and the theoretical yield can reach 100%. The method of the present invention is simple to operate, the raw materials and reagents are readily available, the reaction conditions are mild, the substrate universality is wide, the functional group compatibility is good, the reaction has high enantioselectivity (77%˜96% ee), and the reaction is well compatible with complex natural products or substrates of a drug molecular skeleton. The highly optically active allenoic acid compound obtained by the present invention can be used as an important intermediate for constructing a γ-butyrolactone compound containing a tetra-substituted chiral quaternary carbon center, tetra-substituted allenol, tetra-substituted allenal, tetra-substituted allenyl ketone, tetra-substituted allenami de and other compounds.

Classes IPC  ?

• C07C 51/12 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par réaction avec du monoxyde de carbone sur un groupe contenant de l'oxygène d'un composé organique, p. ex. d'un alcool
• B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
• B01J 31/22 - Complexes organiques
• B01J 31/24 - Phosphines
• C07C 59/52 - Composés non saturés contenant des groupes hydroxyle ou O-métal un groupe hydroxyle ou O-métal étant lié à un atome de carbone d'un cycle aromatique à six chaînons

Abrégé

A Beclin 1-targeting stapled peptide and a pharmaceutical composition. The stapled peptide includes an amino acid sequence at least 66.7% identical to amino acid residues 191-205 of Beclin 1, an amino acid residue E195 and an amino acid residue N202 in the stapled peptide are connected by a hydrocarbon staple to stabilize the α-helical structure of the stapled peptide. The hydrocarbon staple is located at a position in the stapled peptide closer to the Beclin1 coiled coil domain-stapled peptide binding interface, which can enhance the binding affinity of the stapled peptide to Beclin 1 by 10-30 fold. Compared to other autophagy inducers like rapamycin and Tat-Beclin 1 peptide, the optimized stapled peptide shows the unique profile of not only inducing autophagy but also significantly enhancing the endolysosomal degradation of cell surface oncogenic receptors EGFR and HER2 in HER2-positive cancer cells.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides